Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 23;56(1):2001369.
doi: 10.1183/13993003.01369-2020. Print 2020 Jul.

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?

Norbert Ndjeka  1   2 , Francesca Conradie  3   2 , Graeme Meintjes  4 , Anja Reuter  5 , Jennifer Hughes  6 , Xavier Padanilam  7 , Nazir Ismail  8 , Yulene Kock  9 , Iqbal Master  10 , Rodolfo Romero  11 , Julian Te Riele  12 , Martin Enwerem  13 , Hannetjie Ferreira  14 , Gary Maartens  4
Affiliations

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?

Norbert Ndjeka et al. Eur Respir J. .

Abstract

Rapid adoption of new diagnostic tools, parallel process of research and implementation, decentralisation of services, the use of personal protective equipment, as well as strong partnership and collaboration, could strengthen the fight against COVID-19 https://bit.ly/2XupDNe

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: N. Ndjeka has nothing to disclose. Conflict of interest: F. Conradie has nothing to disclose. Conflict of interest: G. Meintjes has nothing to disclose. Conflict of interest: A. Reuter has nothing to disclose. Conflict of interest: J. Hughes has nothing to disclose. Conflict of interest: X. Padanilam has nothing to disclose. Conflict of interest: N. Ismail has nothing to disclose. Conflict of interest: Y. Kock has nothing to disclose. Conflict of interest: I. Master has nothing to disclose. Conflict of interest: R. Romero has nothing to disclose. Conflict of interest: J. te Riele has nothing to disclose. Conflict of interest: M. Enwerem has nothing to disclose. Conflict of interest: H. Ferreira has nothing to disclose. Conflict of interest: G. Maartens has nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier survival curves for a) multidrug/rifampicin-resistant tuberculosis and b) extensively drug-resistant tuberculosis, by regimen inclusive of bedaquiline (Bdq), with 95% confidence intervals, for patients started on treatment between 1 July, 2014 and 31 March, 2016. Reproduced with permission from the publisher [5].
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-h... Rolling Updates on Coronavirus Disease (COVID-19). Date last accessed: 20 April 2020.
    1. Johns Hopkins University Johns Hopkins Coronavirus Dashboard. Track the Coronavirus Outbreak on Johns Hopkins Live Dashboard. https://coronavirus.jhu.edu/map.html Date last accessed: 14 May 2020.
    1. World Health Organization (WHO) Global TB Report. Geneva, WHO, 2019. Available from: www.who.int/tb/global-report-2019
    1. Ndjeka N, Schnippel K, Master I, et al. . High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J 2018; 52: 1801528. doi:10.1183/13993003.01528-2018 - DOI - PubMed
    1. Schnippel K, Ndjeka NO, Maartens G, et al. . Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 2018; 6: 699–706. doi:10.1016/S2213-2600(18)30235-2 - DOI - PubMed

MeSH terms